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Plexiform neurofibromas constitute a serious burden for patients with neurofibromatosis type 1 (NF1), a
common autosomal dominant disorder characterized by pigmentary changes and tumorous skin lesions
(neurofibromas). Despite the prominence of these benign tumors in NF1 patients, the mechanisms underlying
the tumor-associated loss of heterozygosity (LOH) in plexiform neurofibromas have not been extensively
studied. We performed LOH analysis on 43 plexiform neurofibromas from 31 NF1 patients, the largest study of
its kind to date. A total of 13 (30%) plexiform neurofibromas exhibited LOH involving 17q markers. In three
tumors, LOH was found to be confined to the NF1 gene region. However, in none of the tumors was a somatic
NF1 microdeletion, mediated by non-allelic homologous recombination between either NF1-REPs or SUZ12
genes, detected. Thus, NF1 microdeletions do not appear to be frequent somatic events in plexiform
neurofibromas. Determination of NF1 gene copy number by multiplex ligation-dependent probe amplification
indicated that although tumors with smaller regions of LOH were characterized by 17q deletions, no NF1 gene
copy number changes were detected in six plexiform neurofibromas with more extensive LOH. To our
knowledge, mitotic recombination has not previously been reported to be a frequent cause of LOH in plexiform
neurofibromas.
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INTRODUCTION
Neurofibromatosis type 1 (NF1; MIM#162200) is a common
autosomal dominant disorder caused by mutations of the NF1
gene located at 17q11.2. Whereas the vast majority of NF1
patients have inherited subtle mutations within the NF1 gene
(Messiaen et al., 2000), large deletions in 17q11.2, which
result in the loss of the entire NF1 gene and its flanking
regions, occur in B5% of NF1 patients (Kluwe et al., 2004).
Two types of such recurring gross deletion have been noted:
type-1 deletions span 1.4 Mb and have breakpoints within
low-copy repeats, the NF1-REPs a and c (Dorschner et al.,
2000; Jenne et al., 2001; Lo´pez-Correa et al., 2001; De Raedt
et al., 2006a). Type-2 deletions are somewhat smaller,
encompassing only 1.2 Mb, and their breakpoints are located
in the SUZ12 gene and its pseudogene adjacent to the NF1-
REPs (Kehrer-Sawatzki et al., 2004; Steinmann et al., 2007).
Such large deletions of the NF1 gene region have been termed
‘‘NF1 microdeletions’’ because they are too small to be visible
by cytogenetic analysis. The mutational mechanism under-
lying the majority of NF1 microdeletions is non-allelic
homologous recombination (NAHR). Two preferred regions
of NAHR in NF1 type-1 deletions have been noted within the
NF1-REPs, viz. the paralogous recombination sites PRS1 and
PRS2 spanning 1.8 and 3.4 kb (kilobase pairs), respectively
(Forbes et al., 2004; De Raedt et al., 2006a). In contrast to the
situation with type-1 deletions, preferred breakpoint regions
that are locally restricted to a few kilobase pairs have not been
observed in type-2 deletions. Instead, the breakpoint regions of
the 13 type-2 deletions so far characterized are dispersed over
some 32 kb of the 64 kb-spanning SUZ12 gene (Steinmann
et al., 2007).
Clinically, NF1 is characterized by pigmentary anomalies
such as cafe´-au-lait spots and freckling, as well as the
eponymous skin neurofibromas derived from the cutaneous
or subcutaneous nerve sheath (summarized in Huson and
Hughes, 1994). Dermal neurofibromas are benign tumors
with a bump-like appearance, growing in or under the skin.
By contrast, plexiform neurofibromas grow in and along the
peripheral nerves and may involve multiple branches, nerve
roots and plexi. Some 30% of NF1 patients have plexiform
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neurofibromas (Huson et al., 1988, reviewed by Ferner and
Gutmann, 2002), whereas multiple plexiform neurofibromas
are observed in 9–21% of NF1 patients (Huson et al., 1988;
Friedman and Birch, 1997; Waggoner et al., 2000). In
contrast to dermal neurofibromas, plexiform neurofibromas
have the potential to undergo transformation into malignant
peripheral nerve sheath tumors (MPNSTs) and it has been
estimated thatB4–5% actually do so (Ducatman et al., 1986;
Huson and Hughes, 1994). Indeed, most NF1-associated
malignant peripheral nerve sheath tumors arise in preexisting
plexiform neurofibromas. Although the molecular changes
accompanying the malignant transformation of plexiform
neurofibromas are still largely unknown, the hemizygous
inactivation of the TP53 gene, involving either intragenic
mutation or loss of heterozygosity (LOH), has been noted in
MPNSTs. It has been suggested that the hemizygous
inactivation of TP53 may be sufficient to promote malignant
progression since the biallelic inactivation of TP53 in
MPNSTs appears to be rare (Lothe et al., 2001; Upadhyaya
et al., 2008). Plexiform neurofibromas have not however
been studied comprehensively with respect to LOH of the
TP53 gene. Indeed, only one study has so far addressed this
question, and LOH in 17p was not observed in the 10
plexiform neurofibromas investigated (Rasmussen et al.,
2000). Many plexiform neurofibromas are likely to be
congenital lesions since, in a clinic-based study, 44% of
plexiform neurofibromas were found to have been diagnosed
before the age of 5 years (Waggoner et al., 2000). Plexiform
and dermal neurofibromas contain the same cell types,
including Schwann cells, fibroblasts, perineurial cells, axons
and inflammatory mast cells, which are embedded in an
excessive extracellular matrix. An estimated 60–80% of cells
within neurofibromas constitute Schwann cells, the tumor
progenitor cells (Kluwe et al., 1999; Rutkowski et al., 2000;
Serra et al., 2000; Maertens et al., 2006).
The NF1 gene product, neurofibromin, acts as a tumor
suppressor, serving as a negative regulator of ras proteins by
stimulating their intrinsic GTPase activity. Cells lacking
neurofibromin have higher levels of activated ras and exhibit
increased proliferation (Basu et al., 1992; DeClue et al., 1992).
According to the ‘‘two-hit’’ model of tumorigenesis, both
copies of the NF1 gene are inactivated in benign and malignant
tumors from NF1 patients (Sawada et al., 1996 and references
in Table 1; Legius et al., 1993). The somatic inactivation of the
NF1 gene associated with tumorigenesis can be caused either
by mechanisms leading to LOH or by intragenic mutation.
Although LOH has been studied extensively in dermal
neurofibromas, only some 39 plexiform neurofibromas have
been previously investigated in relation to LOH at the NF1
gene locus (as summarized in Table 1). Further, the paucity of
polymorphic markers employed in these latter studies pre-
cluded a more precise estimation of the extent of LOH.
Here, we have investigated the extent of LOH in 43
plexiform neurofibromas. The primary aims were to identify
the mechanisms leading to LOH in these tumors and to
determine whether or not NAHR between duplicated
sequences in the NF1 gene region (either between the NF1-
REPs or between the SUZ12 gene and its pseudogene) is a
frequent event leading to LOH in the plexiform neurofibro-
mas of NF1 patients.
RESULTS
A total of 43 plexiform neurofibromas from 31 patients were
investigated for LOH on chromosome 17. Of the 43, 13
tumors exhibited LOH on 17q but not on 17p (30%; Figure 1).
Five tumors exhibited LOH of at least 52 Mb including almost
the entire length of chromosome 17q, whereas eight tumors
exhibited more restricted LOH. Three tumors displayed LOH
that was confined to markers located within the NF1
microdeletion region (317-1, 390 and 337-5) (Figure 1).
All 43 plexiform neurofibromas were investigated with
respect to whether they were positive for PCR fragments
spanning the breakpoints of NF1 microdeletions comparable
to those previously observed in patients with constitutional
type-1 or mosaic type-2 deletions (De Raedt et al., 2006a;
Steinmann et al., 2007). Although we detected LOH that
was confined to the NF1 microdeletion interval in only
three tumors, all 43 neurofibromas were tested in an
attempt to estimate the frequency of such deletions.
Investigating the presence of somatic NF1 microdeletions
Table 1. Summary of previous studies of LOH in
dermal and plexiform neurofibromas together with the
results obtained in the present analysis
Number of
Dermal
neurofibromas
investigated
(with LOH)
Plexiform
neurofibromas
investigated
(with LOH) Reference
— 43 (13) (30%) This study
23 (5) (22%) — Spurlock et al. (2007)
192 (60) (31%) Serra et al. (2007)
38 (3) (8%) — Maertens et al. (2006)
28 (6) (21%)1 — De Raedt et al. (2006b)
— 3 (1) Frahm et al. (2004)
80 (14) (29%) 3 (0) Upadhyaya et al. (2004)
33 (3) (9%) — Wiest et al. (2003)
126 (32) (25%) — Serra et al. (2001a, b)
6 (1) (17%) 1 (1) Eisenbarth et al. (2000)
74 (10) (14%) 3 (0) John et al. (2000)
15 (2) (13%) 10 (4) (40%) Rasmussen et al. (2000)
— 14 (8) (57%) Kluwe et al. (1999)
60 (15) (25%) — Serra et al. (1997)
38 (0) 5 (1) (20%) Da¨schner et al. (1997)
22 (8) (36%) — Colman et al. (1995)
15 (0) Lothe et al. (1995)
LOH, loss of heterozygosity.
1In addition to these 28 neurofibromas from patients with intragenic
mutations, De Raedt et al. (2006b) investigated 40 neurofibromas from
patients with constitutional gross deletions in the NF1 gene region.
However, none of the 40 tumors exhibited LOH.
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by breakpoint-junction PCR offers the advantage of being
able to detect even quite small numbers of cells carrying
these deletions, if present, despite a possible high background
of cells lacking the deletion. We tested all 43 neurofibromas
in order to include those tumors where LOH could have been
obscured by the presence of cells lacking LOH. The primers
used for these analyses were designed so as to span those
regions of the SUZ12 gene or the NF1-REPs already known to
harbor breakpoints of constitutional or somatic deletions in
patients with NF1 (Table S3). These analyses included
breakpoint-spanning PCRs used to amplify across the deletion
hotspots noted in type-1 deletions (PRS1 and PRS2) and a
total of seven PCRs designed to detect type-2 deletions as
observed in patients with somatic mosaicism for type-2 NF1
microdeletions. However, in none of the tumor-derived DNA
samples were deletion-junction PCR products amplified. The
presence of such fragments would have been indicative of
somatic NF1 microdeletions with breakpoints in the respec-
tive regions.
In order to determine whether the LOH observed in the 13
neurofibromas was caused by deletions, multiplex ligation-
dependent probe amplification (MLPA) analysis was per-
formed using probes located within the NF1 gene region.
Seven of the thirteen tumors were found to exhibit deletions
(Table S4), mostly those tumors that were characterized by
the more restricted LOH 317-1, 335-3, 337-5, 338-2, 390,
913-5, and 612-1 (Figure 1). No NF1 gene copy number
changes were detected in the other six tumors with LOH.
DISCUSSION
Several studies have previously identified an LOH, within the
region of 17q harboring the NF1 gene, in plexiform and
dermal neurofibromas. The percentage of dermal neuro-
fibromas exhibiting LOH ranges from 8 to 36%, whereas in
plexiform neurofibromas, LOH has been detected in 20–57%
of tumors (Table 1). In this study, 13 of 43 (30%) plexiform
neurofibromas exhibited LOH. The rationale of the LOH
studies of plexiform neurofibromas performed here was to
characterize the extent of LOH on chromosome 17, to
determine the mechanism underlying LOH and to measure
the frequency of somatic duplicon-mediated NF1 microdele-
tions in these tumors. We have further investigated the
frequency of loss of the TP53 gene (located on 17p13.1) in
order to explore whether it is possible at an early stage to
identify those plexiform neurofibromas that have the poten-
tial to progress towards malignancy.
The proportion of plexiform neurofibromas exhibiting
LOH in our study (30%) may represent a conservative
estimate of the actual prevalence of LOH in NF1-associated
plexiform neurofibromas because the presence of LOH
could have been concealed in some neurofibromas by
nontumor cells that lack LOH. Both plexiform and
dermal neurofibromas are heterogeneous with respect to
their cellular components but only the Schwann cells
experience the somatic inactivation of the wild-type NF1
allele and are consequently considered to be the tumor
progenitor cells (Kluwe et al., 1999; Rutkowski et al., 2000;
Maertens et al., 2006; Serra et al., 2000, 2001a, b). The
heterogeneous cellular composition of neurofibromas, and in
particular the nontumor cell background (of NF1(þ /)
genotype), hampers the analysis of somatic NF1 gene
inactivation events. De Raedt et al. (2006b) observed that
the percentage of cells exhibiting LOH in dermal neurofi-
bromas varied between 30 and 75%. Consequently, LOH
Position (Mb) Marker
D17S796
D17S1353
D17S720
D17S804
D17S520
D17S783
D17S975
D17S1307
D17S2237
IVS27TG24.8
IVS27TG28.4
D17S1166
D17S1800
D17S1880
D17S907
D17S1788
D17S1861
D17S1809
D17S668
D17S827E
D17S928
D17S632
D17S1402E
LOH of almost the entire 17q
D17S1666
p53
6.19
cen
17p
17p
7.52
605-1 385 952-8 389-2 604-4 374-4 913-5 338-2 612-1337-5 390 317-1335-3
7.55
7.63
9.80
10.20
22.33
25.12
26.49
26.64
26.66
26.66
26.67
26.96
27.20
28.03
30.89
33.16
40.16
60.12
77.62
77.79
77.84
78.00
78.49
Figure 1. LOH analysis in 13 plexiform neurofibromas. Tumor acronyms are indicated above. In those seven tumors highlighted with gray rectangles, LOH was
caused by a deletion according to MLPA. The markers located in the NF1 microdeletion interval are underlined. Black circles: LOH, white circle: no LOH,
striped circles: marker not informative, and gray filled circle: not determined.
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may be difficult to detect if the number of NF1(þ /) cells
is high.
Our inability to detect LOH in some neurofibromas may
however also have been a consequence of the inactivation of
the wild-type NF1 allele by intragenic mutation rather than
by LOH. Indeed, Maertens et al. (2006) identified subtle
intragenic point mutations in 26 of 38 neurofibroma-derived
Schwann cell cultures and only three of these exhibited LOH.
Similarly, subtle somatic NF1 gene mutations were noted in
13 of 33 dermal neurofibromas from two NF1 patients,
whereas LOH was detected in only three dermal neuro-
fibromas (Wiest et al., 2003).
In our study, seven patients were included from whom two
or more plexiform neurofibromas were analyzed (Table S1).
In four of these patients (nos. 1221, 290, 390, and 784), LOH
was found in one but not the other plexiform neurofibroma
investigated. LOH was not, however, observed in any of the
plexiform neurofibromas from the remaining three patients
from whom we analyzed multiple tumors. At present, the
number of patients from whom we could obtain different
plexiform neurofibromas is too small for any firm conclusions
to be drawn with respect to a possible individual predisposi-
tion to acquire preferentially specific type(s) of NF1 gene
mutations (whether subtle gene mutations or LOH involving
17q) as a second hit.
LOH of multiple markers distributed along 17q was
observed in 5 of the 13 LOH-positive plexiform neurofibro-
mas identified here, and was indicative either of the presence
of large deletions or mitotic recombination involving
extended regions of 17q. However, in none of the plexiform
neurofibromas investigated here did the LOH include 17p.
Thus, in none of the 13 LOH-positive tumors was the LOH
due to the loss of the entire chromosome 17.
In three plexiform neurofibromas, LOH appeared to be
confined to the NF1 microdeletion interval (Figure 1, tumors
337-5, 390, and 317-1). In a previously studied series of 126
dermal neurofibromas, which included sufficient markers
from within the NF1 gene region to permit investigation with
high definition, LOH of the region bounded by the NF1-REPs
a and c was observed in three dermal neurofibromas (Serra
et al., 2001b).
It is possible that in the tumors with LOH confined to the
NF1 microdeletion interval, the mechanism resulting in LOH
could have been NAHR, either between the NF1-REPs or the
SUZ12 sequences, as already described in constitutional and
mosaic NF1 microdeletions (De Raedt et al., 2006a;
Steinmann et al., 2007). To investigate the frequency of
LOH in neurofibromas caused by recurring NF1 microdele-
tions, deletion breakpoint-spanning PCRs were performed. In
these experiments, we included not only the tumors in which
LOH was confined to the NF1 microdeletion region, but also
all 43 available tumors in order to determine the overall
frequency of this type of somatic deletion in plexiform
neurofibromas. The deletion breakpoint-spanning PCRs were
designed so as to amplify across the deletion breakpoints
previously identified in NF1 microdeletions. The advantage
of using this PCR-based approach to identify somatic NF1
microdeletions lies in its ability, in principle, to detect
deletion events in small numbers of cells. However, in none
of the 43 tumor samples examined, even those in which LOH
was confined to the NF1 microdeletion interval, were
positive deletion breakpoint-spanning PCR products de-
tected. This implies that somatic NF1 microdeletions,
mediated by NAHR in regions previously identified as
harboring deletion breakpoints in patients with constitutional
and mosaic NF1 microdeletions, are not common events in
plexiform neurofibromas. Interestingly, somatic type-2 NF1
microdeletions were recently identified in leukemia. Screen-
ing of 103 patients without NF1 but with pediatric T-cell
acute lymphoblastic leukemia and 71 patients with acute
myeloid leukemia indicated type-2 NF1 deletions in three
patients with T-cell acute lymphoblastic leukemia and two
patients with acute myeloid leukemia (Balgobind et al.,
2008). Thus, although type-2 NF1 microdeletions occur as
somatic mutations in hematopoietic cells, it would appear as
if they are infrequent events in plexiform neurofibromas.
Differently sized regions of LOH on 17q have been
observed in dermal neurofibromas, but the majority of these
studies did not include enough markers to allow assessment
of whether LOH extended over the entire 17q. In the most
comprehensive study of its kind, 14 microsatellite markers
were analyzed including those located in the most proximal
and distal portions of 17q (Serra et al., 2001b). A total of 27
dermal neurofibromas with LOH were identified, with 19 of
them exhibiting LOH over almost the entire length of 17q. In
another study that employed multiple well-mapped micro-
satellite markers, LOH over the entire 17q was observed in
one of five dermal neurofibromas (Spurlock et al., 2007). If
the results of both studies are taken together, LOH encom-
passing almost the entire 17q has been observed in a total of
20 of 32 dermal neurofibromas (63%) (Serra et al., 2001b;
Spurlock et al., 2007).
By comparison, plexiform neurofibromas have not been
investigated extensively with regard to the extent of LOH. In
one of four plexiform neurofibromas, LOH was observed to
extend over virtually the entire length of 17q (Rasmussen
et al., 2000). The LOH analysis in plexiform neurofibromas
performed here has the highest resolution of all studies so far
performed; LOH spanning almost the entire length of 17q
was noted in 5 of 13 tumors with LOH (Figure 1). Thus, LOH
encompassing 17q would appear to occur at a similar fre-
quency in plexiform neurofibromas as in dermal neurofibromas.
Loss or mutation of the TP53 gene at 17p13.1 has been
frequently observed in NF1-associated MPNSTs and is hence
likely to contribute to the progression towards malignancy
(Upadhyaya et al., 2004, 2008 and references therein). By
contrast, LOH of TP53 has never been found in dermal
neurofibromas. All plexiform neurofibromas investigated by
us retained heterozygosity for markers in 17p, indicating that
LOH did not encompass the TP53 gene. This is in line with
the observations of Rasmussen et al. (2000) who did not
observe LOH at 17p in a total of 10 plexiform neurofibromas.
Taken together, no striking difference exists, with respect to
the extent of LOH on chromosome 17, between dermal and
plexiform neurofibromas. Our study therefore suggests that
the similarity between both subtypes of neurofibroma extends
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to the underlying mechanism of LOH. In addition to
deletions, LOH in dermal neurofibromas has been shown to
be frequently caused by mitotic recombination resulting in
homozygosity of the NF1 germline mutation (Serra et al.,
2001b; De Raedt et al., 2006b). In our study, 7 of 13
plexiform neurofibromas exhibited LOH due to deletions
(Figure 1).
In the other six plexiform neurofibromas with LOH (605-1,
385, 952-8, 389-2, 374-4, and 604-4), no reduction of NF1
copy number was observed, indicating that the LOH in these
tumors was due to mitotic recombination. Mitotic recombi-
nation has also been reported in NF1-associated myeloid
malignancies and gastrointestinal stromal tumors resulting in
reduction to homozygosity of the NF1 germline mutation
(Stephens et al., 2006; Stewart et al., 2007). Our study clearly
indicates that mitotic recombination in 17q is a frequent
cause of LOH in plexiform neurofibromas.
We conclude that there is no significant difference
between dermal and plexiform neurofibromas with respect
to either the extent of LOH on 17q or the underlying
mutational mechanisms. Since mitotic recombination was
observed in 46% of plexiform neurofibromas with LOH, it
may be regarded as a frequent mutational mechanism in
these benign tumors. The progression of a fraction of
plexiform neurofibromas towards malignancy and their
transformation to MPNSTs may thus occur in only a small
subpopulation of tumor cells but could be initiated by genetic
changes that are consequent to LOH on 17q.
MATERIALS AND METHODS
Tumor samples
A total of 43 plexiform neurofibromas (listed in Table S1) derived
from 31 NF1 patients were investigated by PCR analysis to search for
LOH. The patients fulfilled the diagnostic criteria for NF1 (Stumpf
et al., 1988) and all gave their informed consent. Clinical data from
the patients as well as the germline NF1 gene mutation, if known,
are given in Table S1. Ethical approval for this study was obtained by
the local Ethics Committee. Patients included in this study gave
written informed consent. The study was conducted according to the
Declaration of Helsinki Principles. The plexiform neurofibromas
were ascertained by radiological and clinical evaluation.
Tumor tissue was frozen in liquid nitrogen immediately after
excision and stored at 70 1C. DNA was extracted from frozen tissue
and patient blood samples using the Blood & Cell Culture DNA Kit
(Qiagen, Hilden, Germany), following the sample preparation and
lysis protocol for tissue samples.
LOH analysis
LOH was investigated using 25 microsatellite markers from
chromosome 17. The sequences of the primers used for this analysis,
as well as their precise genomic positions on chromosome 17, are
summarized in Table S2. Seven markers are located within the NF1
microdeletion region between the NF1-REPs a and c (Figure 1). PCR
products were analyzed on an ABI 3100 sequencer using a standard
fragment analysis protocol. All markers were analyzed at least twice
by independent PCR experiments. LOH in a tumor sample was
scored when the height ratio of the two marker alleles was at least
20% different from the allele ratio observed in patient peripheral
blood DNA and in blood samples from unaffected probands with the
same allele sizes as those detected in the tumor DNAs.
Breakpoint-junction PCRs
A total of nine primer pairs (listed in Table S3) were used to amplify
across the deletion breakpoints identified in constitutional type-1
NF1 microdeletions and mosaic type-2 microdeletions as described
in previous studies (Jenne et al., 2001; Forbes et al., 2004; De Raedt
et al., 2006a; Steinmann et al., 2007). The positions of the respective
breakpoint regions are shown in Figure S1. To ensure good quality of
the tumor-derived DNA samples, a control PCR was performed with
each tumor DNA (expected size of the PCR product: 3 kb) using
primer BO11f (50-atctttccaccacatggtccc-30, chromosomal position on
7q34: 141,580,595–141,580,615; hg18) and primer BO10r (50-
ccctcaactggattgaaatcacc-30, chromosomal position: 141,583,430–
141,583,452). As positive controls for the deletion junction PCRs,
DNAs were used from patients with known type-1 (with breakpoints
located within PRS1 or PRS2) and type-2 NF1 microdeletions as
indicated in Table S3. Putative breakpoint-junction PCR products
amplified from tumor DNA samples were cloned using the TOPO TA
cloning system (Invitrogen, Karlsruhe, Germany) and at least 20
clones were sequenced in order to avoid false positive PCR products
derived from the proximal or distal duplications (NF1-REPs or
SUZ12 sequences).
In one case of deletion breakpoint-junction PCR (primer
combination hks4033 and jtu¨8r), a restriction enzyme assay using
Tsp45I was performed to determine whether the PCR fragments
amplified from the tumor material were derived from an authentic
breakpoint-spanning fusion between the SUZ12 pseudogene and the
SUZ12 gene or whether the PCR products were instead false
positives having been amplified from either the SUZ12 gene or the
SUZ12 pseudogene.
Multiplex ligation-dependent probe amplification
To determine the NF1 gene copy number in the tumors, the MLPA
assay SALSA P122 NF1 area (version 01, 05-02-2005 MRC Holland,
Amsterdam, The Netherlands) was used. Tumor DNA samples were
analyzed according to the manufacturer’s instructions using 200 ng
genomic DNA. After hybridization, ligation, and amplification, the
PCR products were separated on an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA) by capillary
electrophoresis. The relative probe signal was then determined by
means of a normalization procedure as described by Wimmer et al.
(2006). In those cases where two copies of a sequence are present in
a given sample, this process is expected to yield a value of 1.0. A
decrease in the peak area values to o0.91 for probes in the NF1
gene region was considered to be indicative of a deletion.
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Table S1. Phenotype information on NF1 patients with plexiform neuro-
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Table S2. Primers and genomic positions of the polymorphic markers on
chromosome 17 used for LOH analysis of the plexiform neurofibromas.
Table S3. Sequence and genomic locations of primers used for breakpoint-
spanning PCRs with DNA of 43 plexiform neurofibromas.
Table S4. Results of the MLPA analysis of 13 neurofibromas exhibiting LOH.
Figure S1. Scheme of the NF1 gene region.
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